Evidence map›Paper›PMID 34384490›Full record

ArticleAlzheimer's research & therapy2021

Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project.

Michael L Alosco, Megan L Mariani, Charles H Adler, Laura J Balcer, Charles Bernick, Rhoda Au, Sarah J Banks, William B Barr, Sylvain Bouix, Robert C Cantu and 23 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02798185 (Diagnostics, Imaging And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy), which is not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02798185 completednot on this map

Diagnostics, Imaging And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project

TypeobservationalSponsorBoston UniversityRan2016 to 2023Enrolled240ConditionsChronic Traumatic Encephalopathy
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Factors associated with subjective cognitive complaints in former American football players.Journal of the International Neuropsychological Society : JINS · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 15 institutions in 2 countries.

Michael L AloscoBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Megan L MarianiBoston University CTE Center, Boston University School of Medicine, Boston, MA, USA.
Charles H AdlerDepartment of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Laura J BalcerDepartments of Neurology, Population Health and Ophthalmology, NYU Grossman School of Medicine, New York, NY, USA.
Charles BernickCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Rhoda AuBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Framingham Heart Study, and Slone Epidemiology Center, Boston, MA, USA.
Sarah J BanksDepartments of Neuroscience and Psychiatry, University of California, San Diego, CA, USA.
William B BarrDepartment of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Sylvain BouixPsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Robert C CantuBoston University Alzheimer's Disease Research Center, Departments of Neurology and Neurosurgery, Boston University School of Medicine, Boston, MA, USA.
Michael J ColemanPsychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Boston, MA, USA.
David W DodickDepartment of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Lindsay A FarrerDepartments of Medicine (Biomedical Genetics), Neurology, Ophthalmology, Epidemiology, and Biostatistics, BU Schools of Medicine and Public Health, Boston, MA, USA.
Yonas E GedaAlzheimer's Disease and Memory Disorders Program, Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Douglas I KatzDepartment of Neurology, Boston University School of Medicine, Boston, MA, USA.
Inga K KoertePsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Neil W KowallBoston University Alzheimer's Disease Research Center, Departments of Neurology and Neurosurgery, Boston University School of Medicine, Boston, MA, USA.
Alexander P LinCenter for Clinical Spectroscopy, Department of Radiology, Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Daniel S MarcusDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Kenneth L MarekInstitute for Neurodegenerative Disorders, Invicro, LLC, New Haven, CT, USA.
Michael D McCleanDepartment of Environmental Health, Boston University School of Public Health, Boston, MA, USA.
Ann C McKeeBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Jesse MezBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Framingham Heart Study, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Joseph N PalmisanoBiostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, MA, USA.
Elaine R PeskindVA Northwest Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Yorghos TripodisDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Robert W TurnerDepartment of Clinical Research & Leadership, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Jennifer V WetheDepartment of Psychiatry and Psychology, Mayo Clinic School of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Jeffrey L CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Eric M ReimanBanner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
Martha E ShentonPsychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Robert A SternBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Departments of Neurology, Neurosurgery, and Anatomy & Neurobiology, Boston University School of Medicine, Boston, MA, USA. bobstern@bu.edu.ORCID 0000-0002-5008-077X
DIAGNOSE CTE Research Project Investigators
Boston University · USBrigham and Women's Hospital · USMayo Clinic in Arizona · USBarrow Neurological Institute · USTranslational Genomics Research Institute · USUniversity of California San Diego · USUniversity of Washington · USWashington University in St. Louis · USGeorge Washington University · USNew York University · USUniversity of Nevada, Las Vegas · USBoston Public Schools · USCleveland Clinic · USEncompass Health (United States)Ludwig-Maximilians-Universität München · DE

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI HEATHER Allyson BIMONTE-NELSON · 2021 to 2026
$24.9M
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI Robert J. Fox, Jefferson Kinney · 2015 to 2026
$22.8M
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk FactorsU01NS093334 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CUMMINGS, JEFFREY L., REIMAN, ERIC MICHAEL · 2016 to 2022
$17.0M
NVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI RITTER, AARON · 2020 to 2022
$3.3M
Sex Differences in Brain Structure and Function After Sports-Related ConcussionR01NS100952 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI KOERTE, INGA KATHARINA · 2017 to 2022
$2.9M
Chronic Traumatic Encephalopathy: Clinical Presentation and BiomarkersR01NS078337 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI STERN, ROBERT A · 2011 to 2013
$2.0M
Pathways linking neuropsychiatric symptoms with Alzheimer's disease neuroimaging biomarkers and the outcome of incident Mild Cognitive Impairment/ DementiaR01AG057708 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI GEDA, YONAS E · 2018 to 2022
$1.7M
Black Male Dementia Caregiver Burden: Stress-related Cognitive Dysfunction, and physiological and psychosocial measuresK01AG054762 · NIA · GEORGE WASHINGTON UNIVERSITY · PI TURNER, ROBERT W. · 2017 to 2022
$832k
NIA NIH HHS K01 AG054762NIA NIH HHS P20 AG068053NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG057708NIA NIH HHS T32 AG000172NIGMS NIH HHS P20 GM109025NINDS NIH HHS K00 NS113419NINDS NIH HHS K23 NS102399NINDS NIH HHS R01 NS078337NINDS NIH HHS R01 NS100952NINDS NIH HHS U01 NS093334NINDS NIH HHS U01NS093334
6 · The paper itself

Abstract

backgroundChronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soccer, ice hockey, and rugby players. CTE cannot yet be diagnosed during life. In December 2015, the National Institute of Neurological Disorders and Stroke awarded a seven-year grant (U01NS093334) to fund the "Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project." The objectives of this multicenter project are to: develop in vivo fluid and neuroimaging biomarkers for CTE; characterize its clinical presentation; refine and validate clinical research diagnostic criteria (i.e., traumatic encephalopathy syndrome [TES]); examine repetitive head impact exposure, genetic, and other risk factors; and provide shared resources of anonymized data and biological samples to the research community. In this paper, we provide a detailed overview of the rationale, design, and methods for the DIAGNOSE CTE Research Project.

methodsThe targeted sample and sample size was 240 male participants, ages 45-74, including 120 former professional football players, 60 former collegiate football players, and 60 asymptomatic participants without a history of head trauma or participation in organized contact sports. Participants were evaluated at one of four U.S. sites and underwent the following baseline procedures: neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; and standardized self-report measures of neuropsychiatric, cognitive, and daily functioning. Study partners completed similar informant-report measures. Follow-up evaluations were intended to be in-person and at 3 years post-baseline. Multidisciplinary diagnostic consensus conferences are held, and the reliability and validity of TES diagnostic criteria are examined.

resultsParticipant enrollment and all baseline evaluations were completed in February 2020. Three-year follow-up evaluations began in October 2019. However, in-person evaluation ceased with the COVID-19 pandemic, and resumed as remote, 4-year follow-up evaluations (including telephone-, online-, and videoconference-based cognitive, neuropsychiatric, and neurologic examinations, as well as in-home blood draw) in February 2021.

conclusionsFindings from the DIAGNOSE CTE Research Project should facilitate detection and diagnosis of CTE during life, and thereby accelerate research on risk factors, mechanisms, epidemiology, treatment, and prevention of CTE.

trial registrationNCT02798185.

Indexed as

Chronic Traumatic EncephalopathyCOVID-19Neurodegenerative DiseasesAgedHumansMaleMiddle AgedPandemicsReproducibility of ResultsSARS-CoV-2BiomarkersChronic traumatic encephalopathyCognitive functionCollege footballConcussionFootballHead traumaMRIMRSNational Football LeagueNeurodegenerative diseaseNeuroimagingPositron emission tomographyRemote assessmentRepetitive head impactsSubconcussionTauTraumatic brain injuryTraumatic encephalopathy syndrome

Identifiers

PMID34384490
PMCPMC8357968
OpenAlexW3188554627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.